| 0.83 -0.007 (-0.86%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.23 | 1-year : | 1.44 |
| Resists | First : | 1.05 | Second : | 1.24 |
| Pivot price | 0.9  |
|||
| Supports | First : | 0.75 | Second : | 0.63 |
| MAs | MA(5) : | 0.82 |
MA(20) : | 0.94 |
| MA(100) : | 1.09 |
MA(250) : | 1.01  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.6 |
D(3) : | 9.3 |
| RSI | RSI(14): 35.9 |
|||
| 52-week | High : | 1.45 | Low : | 0.6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ XTNT ] has closed above bottom band by 26.5%. Bollinger Bands are 24.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.9 - 0.9 | 0.9 - 0.91 |
| Low: | 0.79 - 0.79 | 0.79 - 0.8 |
| Close: | 0.82 - 0.83 | 0.83 - 0.84 |
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
Fri, 19 Apr 2024
Xtant Medical (NYSEAMERICAN:XTNT) Shares Cross Above 200 Day Moving Average of $0.00 - MarketBeat
Wed, 10 Apr 2024
Xtant Medical (NYSEAMERICAN:XTNT) Share Price Crosses Above 200-Day Moving Average of $0.00 - MarketBeat
Tue, 02 Apr 2024
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2023 Earnings Call Transcript - Yahoo Finance
Tue, 02 Apr 2024
Xtant Medical's Earnings at Risk: The Unhedged Perils of Currency Fluctuations - TipRanks.com - TipRanks
Mon, 01 Apr 2024
Xtant Medical Holdings Inc (XTNT) Reports Record Revenue in 2023, Outpacing Analyst Estimates - Yahoo Finance
Mon, 01 Apr 2024
Xtant Medical Holdings Inc. (XTNT) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 130 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 69.3 (%) |
| Shares Short | 311 (K) |
| Shares Short P.Month | 340 (K) |
| EPS | 0.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.41 |
| Profit Margin | 3.5 % |
| Operating Margin | -13.6 % |
| Return on Assets (ttm) | -6.9 % |
| Return on Equity (ttm) | 6.3 % |
| Qtrly Rev. Growth | 73 % |
| Gross Profit (p.s.) | 0.24 |
| Sales Per Share | 0.6 |
| EBITDA (p.s.) | -0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | 41.5 |
| PEG Ratio | 6.5 |
| Price to Book value | 1.97 |
| Price to Sales | 1.37 |
| Price to Cash Flow | -9.92 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|